Nitroaromatic antibiotics show activity against anaerobic bacteria and parasites, finding use in the treatment of Heliobacter pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the development of new treatments for these conditions, the associated toxicity and lack of clear mechanisms of action have limited their therapeutic development. Nitroaromatic antibiotics require reductive bioactivation for activity and this reductive metabolism can convert the nitro group to nitric oxide (NO) or a related reactive nitrogen species (RNS). As nitric oxide plays important roles in the defensive immune response to bacterial infection through both signaling and redox-mediated pathways, defining controlled NO generation pathways from these antibiotics would allow the design of new therapeutics. This review focuses on the release of nitrogen oxide species from various nitroaromatic antibiotics to portend the increased ability for these compounds to positively impact infectious disease treatment.
pan class="Chemical">n class="Chemical">Nitroaromatic antibiotics show activity against anaerobic bacteria and pan>rasitpan class="Chemical">es, finding use in the treatment of Heliobacter pan class="Species">pylori infections, tuberculosis, trichomoniasis, human African trypanosomiasis, Chagas disease and leishmaniasis. Despite this activity and a clear need for the development of new treatments for these conditions, the associated toxicity and lack of clear mechanisms of action have limited their therapeutic development. Nitroaromatic antibiotics require reductive bioactivation for activity and this reductive metabolism can convert the nitro group to nitric oxide (NO) or a related reactive nitrogen species (RNS). As nitric oxide plays important roles in the defensive immune response to bacterial infection through both signaling and redox-mediated pathways, defining controlled NO generation pathways from these antibiotics would allow the design of new therapeutics. This review focuses on the release of nitrogen oxide species from various nitroaromatic antibiotics to portend the increased ability for these compounds to positively impact infectious disease treatment.
Authors: Jackson R Hall; Kaitlyn R Rouillard; Dakota J Suchyta; Micah D Brown; Mona Jasmine R Ahonen; Mark H Schoenfisc Journal: ACS Biomater Sci Eng Date: 2019-11-13
Authors: Andrew M Thompson; Patrick D O'Connor; Andrew J Marshall; Adrian Blaser; Vanessa Yardley; Louis Maes; Suman Gupta; Delphine Launay; Stephanie Braillard; Eric Chatelain; Baojie Wan; Scott G Franzblau; Zhenkun Ma; Christopher B Cooper; William A Denny Journal: J Med Chem Date: 2018-03-06 Impact factor: 7.446
Authors: Saúl Noriega; Jaime Cardoso-Ortiz; Argelia López-Luna; Ma Del Refugio Cuevas-Flores; Juan Armando Flores De La Torre Journal: Pharmaceuticals (Basel) Date: 2022-06-05
Authors: Mohammed Salah Ayoup; Ahmed R Rabee; Hamida Abdel-Hamid; Marwa F Harras; Nagwan G El Menofy; Magda M F Ismail Journal: ACS Omega Date: 2022-02-07